Gabapentin Capsule
Product Images NDC 70518-1469

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-1469). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin 400mg 70518 1469 00

Gabapentin 400 mg oral capsules label showing a quantity of 30 capsules. The label includes the proprietary and generic name Gabapentin, dosage strength of 400 mg, and manufacturer RemedyRepack Inc. It features barcodes, a QR code, and storage instructions. The label notes repackaging by RemedyRepack Inc. and manufacturer Ascend Labs, LLC.*

FDA Label Image

Gabapentin 400mg 70518 1469 01

Gabapentin 400 mg oral capsules packaging label showing a quantity of 90 capsules. The label includes the brand RemedyRepack and indicates repackaging by RemedyRepack Inc. The label features an NDC number 70518-1469-01, manufacturer information from Ascend Labs, LLC in Montvale, NJ, and storage instructions. A barcode and a QR code are also present on the label.*

FDA Label Image

Gabapentin 400mg 70518 1469 02

Gabapentin 400 mg capsule label showing a quantity of 180 capsules. The label is from RemedyRepack Inc., repackaged in Indiana, PA. The manufacturer listed is Ascend Labs, LLC, Montvale, NJ. It includes the NDC number 70518-1469-02 and storage instructions between 20-25°C (68-77°F).*

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

Equation for calculating creatinine clearance (CLCr) based on age, weight, and serum creatinine, with an adjustment factor for female patients. The formula is presented as text with mathematical notations.*

FDA Label Image

Gabapentin Fig1

A line graph depicting mean pain score over 8 weeks comparing placebo and Gabapentin 3600 mg/day. The x-axis shows weeks from baseline to 8, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores ranging from 0 to 10. Gabapentin shows a decreasing pain score trend, while placebo remains relatively stable.*

FDA Label Image

Gabapentin Fig2

A line graph showing mean pain scores over 7 weeks for Placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day groups. The timeline is divided into a 3-week dose titration period and a 4-week fixed dose period. Gabapentin groups show a greater reduction in pain scores compared to Placebo over time.*

FDA Label Image

Gabapentin Fig3

Bar chart showing the proportion of responders with at least 50% reduction in pain score at endpoint in controlled postherpetic neuralgia (PHN) studies. Two studies are presented: Study 1 compares placebo (PBO) at 12% with gabapentin (GBP) 3600 mg at 29%; Study 2 compares placebo (PBO) at 14% with gabapentin 1800 mg at 32% and gabapentin 2400 mg at 34%. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Gabapentin-fig4 (Gabapentin Fig4)

A scatter plot comparing the percentage difference versus daily dose (mg) for Gabapentin across three studies labeled a, b, and c. The chart uses different colored squares to represent each study and shows data points at doses approximately 600 mg, 900 mg, 1200 mg, and 1800 mg, with percentage differences ranging from about 7% to 18%.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.